Innate Pharma announces its participation to major upcoming medical meetings

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will report clinical data for its two lead clinical drug candidate at the following June’s medical meetings: EHA and ASCO

• At the Annual European Hematology Association (“EHA”) Meeting, in Barcelona, Spain, on June 13, 2010:

Final data from the Phase I/II clinical trial evaluating IPH 1101 in combination with rituximab in follicular non-Hodgkin’s lymphoma (“fNHL”) patients (study “IPH 1101-202”) will be subject to an oral presentation by Pr Jean-François Rossi (Head of Hemato-Oncology Department and Center of Clinical Investigation BT 509, University Hospital, Montpellier, France), co-lead investigator of the study (Abstract 1131, A phase I/II study of IPH1101, gamma delta T cell agonist, in combination with rituximab re-treatment, in patients with low grade follicular lymphoma).
Innate Pharma management will host a conference call to discuss these results on June 14, 2010. More details to connect to this conference call will be provided in the press release reporting the results and on the website.

• At the Annual American Society of Clinical Oncology (“ASCO”) Meeting, in Chicago, Illinois, USA, on June 5, 2010:

Updated interim data for the Phase I trial with IPH 2101 in Multiple Myeloma patients (study “IPH 2101-103”). The interim results will be subject to a poster presented by Don Benson, MD, PhD (Division of Hematology/Oncology, Ohio State Cancer Center, Columbus, OH), during the Lymphoma and Plasma Cell Disorders session (Abstract 8139, A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma).